The Patent Finder
BM

Biogen Ma Inc.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

236 patents currently held

82 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Jan 2027. from the record

Of the 82 now held by other companies, 20 were conveyed to Bioverativ Therapeutics Inc. in the filing they arrived in, and 62 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
48
Ending by 2030
Jan 2027
Next term end
161
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 30, 2026
    The maintenance fee for Medical Diagnostic and Treatment Systems and Their Methods of Use (US 11,660,054) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
  • 1 fee due Dec 4, 2026
    The maintenance fee for Methods of Preventing and Removing Trisulfide Bonds (US 10,308,706) comes due Dec 4, 2026. Unpaid by Jun 4, 2027, it lapses early.
  • 5 fees due Jan 2 to 30, 2027 · next Jan 2
  • 8 fees due Feb 4 to 27, 2027 · next Feb 4
  • 6 fees due Mar 3 to 24, 2027 · next Mar 3
  • 3 fees due Apr 8 to 24, 2027 · next Apr 8
  • 5 fees due May 10 to 28, 2027 · next May 10
  • 5 fees due Jun 1 to 26, 2027 · next Jun 1
  • 3 fees due Jul 2 to 12, 2027 · next Jul 2
  • 5 fees due Aug 4 to 20, 2027 · next Aug 4
  • 3 fees due Sep 1 to 17, 2027 · next Sep 1
  • 1 fee due Oct 19, 2027
    The maintenance fee for Assay for JC Virus Antibodies (US 9,316,641) comes due Oct 19, 2027. Unpaid by Apr 19, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 5 of the patents on this record were granted since Aug 17, 2026
  • 6 terms have ended since Aug 17, 2026

What they patent

The 5 largest of its 161 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Treatment for Multiple Sclerosis9 in forceto Nov 2035
Inhibiting Agents for Bruton's Tyrosine Kinase5 in forceto Apr 2038
Method of Assessing Risk of PML5 in forceto Jun 2034
S1P Modulating Agents5 in forceto Feb 2032
ANTI-VLA-4 Related Assays5 in forceto Feb 2031

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 9,228,015Nogo Receptor Antagonists and Methods of Increasing Neurite Outgrowth
In force
 · High confidence
In forceHigh confidence
US 10,233,245Methods of Treating Inflammatory and Autoimmune Diseases with Natalizumab
In force
 · Low confidence
In forceLow confidence
US 11,292,845Methods of Treating Inflammatory and Autoimmune Diseases with Natalizumab
In force
 · Medium confidence
In forceMedium confidence
US 10,466,251Methods of Treating Inflammatory and Autoimmune Diseases with Natalizumab
In force
 · Medium confidence
In forceMedium confidence
US 11,333,670Methods of Treating Inflammatory and Autoimmune Diseases with Natalizumab
In force
 · Low confidence
In forceLow confidence
US 12,607,638Methods of Treating Inflammatory and Autoimmune Diseases with Natalizumab
In force
 · Low confidence
In forceLow confidence
US 9,493,567Methods of Treating Inflammatory and Autoimmune Diseases with Natalizumab
In force
 · Medium confidence
In forceMedium confidence
US 8,992,924Anti-Alpha V Beta 6 Antibodies and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 7,576,101Composition for and Treatment of Demyelinating Diseases and Paralysis by Administration of Remyelinating Agents
In force
 · High confidence
In forceHigh confidence
US 8,017,733Polyalkylene Polymer Compounds and Uses Thereof
In force
 · Medium confidence
In forceMedium confidence
10 of 236 patents shown.
Pro members see all 236.
Pro members: see all 236 patents
Also on record, not counted in the 236: 82 patents in force now held by others · 222 patents ended · 102 applications pending · 324 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited